



**HAL**  
open science

## Semaphorin-Plexin Signaling: From Axonal Guidance to a New X-Linked Intellectual Disability Syndrome

Jacqueline L Steele, Michelle M Morrow, Harvey B Sarnat, Ebba Alkhunaizi, Tracy Brandt, David A Chitayat, Colette P Defilippo, Ganka V Douglas, Holly A Dubbs, Houda Zghal Elloumi, et al.

► **To cite this version:**

Jacqueline L Steele, Michelle M Morrow, Harvey B Sarnat, Ebba Alkhunaizi, Tracy Brandt, et al.. Semaphorin-Plexin Signaling: From Axonal Guidance to a New X-Linked Intellectual Disability Syndrome. *Pediatric Neurology*, 2022, 126, pp.65-73. 10.1016/j.pediatrneurol.2021.10.008 . hal-04534072

**HAL Id: hal-04534072**

**<https://hal.sorbonne-universite.fr/hal-04534072>**

Submitted on 5 Apr 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License



ELSEVIER

Contents lists available at ScienceDirect

## Pediatric Neurology

journal homepage: [www.elsevier.com/locate/pnu](http://www.elsevier.com/locate/pnu)

## Original Article

## Semaphorin-Plexin Signaling: From Axonal Guidance to a New X-Linked Intellectual Disability Syndrome



Jacqueline L. Steele, BS <sup>a</sup>, Michelle M. Morrow, PhD <sup>b</sup>, Harvey B. Sarnat, MD <sup>c</sup>, Ebba Alkhunaizi, MD <sup>d</sup>, Tracy Brandt, PhD <sup>b</sup>, David A. Chitayat, MD <sup>d</sup>, Colette P. DeFilippo, MS, CGC <sup>e</sup>, Ganka V. Douglas, PhD <sup>b</sup>, Holly A. Dubbs, MS, CGC <sup>f</sup>, Houda Zghal Elloumi, PhD <sup>b</sup>, Megan R. Glassford, MMSc, CGC <sup>g</sup>, Mark C. Hannibal, MD, PhD <sup>g</sup>, Bénédicte Héron, MD <sup>h</sup>, Linda E. Kim, MD <sup>i</sup>, Elysa J. Marco, MD <sup>j</sup>, Cyril Mignot, MD <sup>k</sup>, Kristin G. Monaghan, PhD <sup>b</sup>, Kenneth A. Myers, MD, PhD <sup>l</sup>, Sumit Parikh, MD <sup>m</sup>, Shane C. Quinonez, MD <sup>g</sup>, Farrah Rajabi, MD <sup>n</sup>, Suma P. Shankar, MD, PhD <sup>e</sup>, Marwan S. Shinawi, MD <sup>o</sup>, Jiddeke J.P. van de Kamp, MD <sup>p</sup>, Aravindhyan Veerapandiyan, MD <sup>q</sup>, Amy T. Waldman, MD <sup>f</sup>, William D. Graf, MD <sup>r,\*</sup>

<sup>a</sup> University of Connecticut School of Medicine, Farmington, Connecticut

<sup>b</sup> GeneDx, Inc., Gaithersburg, Maryland

<sup>c</sup> Departments of Paediatrics, Pathology (Neuropathology), and Clinical Neurosciences, University of Calgary Cumming School of Medicine and Alberta Children's Hospital Research Institute, Calgary, Alberta, Canada

<sup>d</sup> Department of Obstetrics and Gynecology, The Prenatal Diagnosis and Medical Genetics Program, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada

<sup>e</sup> Division of Genomic Medicine, Department of Pediatrics, MIND Institute, University of California-Davis, Sacramento, California

<sup>f</sup> Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

<sup>g</sup> Division of Pediatric Genetics, Metabolism and Genomic Medicine, Department of Pediatrics, C. S. Mott Children's Hospital, University of Michigan, Ann Arbor, Michigan

<sup>h</sup> Hôpital Armand Trousseau, Service de Neurologie Pédiatrique, Paris, France

<sup>i</sup> Department of Laboratory Medicine and Genetics, Trillium Health Partners, Mississauga, Ontario, Canada

<sup>j</sup> Department of Neurodevelopmental Medicine, CorticaCare, San Diego, California

<sup>k</sup> Clinical Genetic Department, Pitié Salpêtrière University Hospital, Paris, France

<sup>l</sup> Division of Neurology, Department of Pediatrics, McGill University Health Centre, Montreal, Canada

<sup>m</sup> Department of Mitochondrial Medicine & Genetics, Cleveland Clinic, Cleveland, Ohio

<sup>n</sup> Division of Genetics and Genomics, Boston Children's Hospital; Department of Pediatrics, Harvard Medical School, Boston, Massachusetts

<sup>o</sup> Division of Genetics and Genomic Medicine, Department of Pediatrics, Washington University School of Medicine, St Louis, Missouri

<sup>p</sup> Clinical Genetics, Amsterdam University Medical Centers, Amsterdam Netherlands

<sup>q</sup> Division of Neurology, Department of Pediatrics, Arkansas Children's Hospital, Little Rock, Arkansas

<sup>r</sup> Division of Neurology, Department of Pediatrics, Connecticut Children's, University of Connecticut, Farmington, Connecticut

Authorship contributions: Conception and design of the study, or acquisition of data, or analysis and interpretation of data: J.L.S., M.M.M., W.D.G.; drafting the article or revising it critically for important intellectual content: J.L.S., M.M.M., H.B.S., K.A.M., M.S.S., W.D.G.; final approval of the version to be submitted: J.L.S., M.M.M., H.B.S., E.A., T.B., D.A.C., C.P.D., G.V.D., H.A.D., H.Z.E., M.R.G., M.C.H., B.H., L.E.K., E.J.M., C.M., K.G.M., K.A.M., S.P., S.C.Q., F.R., M.S.S., S.P.S., J.J.P.v.d.K., A.V., A.T.W., W.D.G.

Summary Declaration of Interest Statement: Jacqueline L. Steele, BS: UConn School of Medicine Summer Research Program; Michelle M. Morrow, PhD, Tracy Brandt, PhD, Ganka V. Douglas, PhD, Houda Zghal Elloumi, PhD, and Kristin G.

Monaghan, PhD: Employee of GeneDx, Inc; Kenneth A. Myers, MD, PhD: Dr. Myers reports research support from LivaNova and GeneTx, and grants from Dravet Canada, Fonds de Recherches du Québec–Santé, Koolen-de Vries Foundation, Savoy Foundation, Liam Foundation, and Research Institute of the McGill University Health Centre. All other authors declared none.

\* Communications should be addressed to: Dr. Graf; Division of Neurology; Department of Pediatrics; Connecticut Children's and The University of Connecticut; Farmington, CT.

E-mail address: [wgraf@connecticutchildrens.org](mailto:wgraf@connecticutchildrens.org) (W.D. Graf).

<https://doi.org/10.1016/j.pediatrneurol.2021.10.008>

0887-8994/© 2021 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## ARTICLE INFO

## Article history:

Received 4 October 2021

Accepted 10 October 2021

Available online 18 October 2021

## Keywords:

PLXNA3

Plexin

Semaphorin

Neurodevelopment

Intellectual disability

Autism

## ABSTRACT

**Background:** Semaphorins and plexins are ligands and cell surface receptors that regulate multiple neurodevelopmental processes such as axonal growth and guidance. *PLXNA3* is a plexin gene located on the X chromosome that encodes the most widely expressed plexin receptor in fetal brain, plexin-A3. Plexin-A3 knockout mice demonstrate its role in semaphorin signaling *in vivo*. The clinical manifestations of semaphorin/plexin neurodevelopmental disorders have been less widely explored. This study describes the neurological and neurodevelopmental phenotypes of boys with maternally inherited hemizygous *PLXNA3* variants.

**Methods:** Data-sharing through GeneDx and GeneMatcher allowed identification of individuals with autism or intellectual disabilities (autism/ID) and hemizygous *PLXNA3* variants in collaboration with their physicians and genetic counselors, who completed questionnaires about their patients. *In silico* analyses predicted pathogenicity for each *PLXNA3* variant.

**Results:** We assessed 14 boys (mean age, 10.7 [range 2 to 25] years) with maternally inherited hemizygous *PLXNA3* variants and autism/ID ranging from mild to severe. Other findings included fine motor dyspraxia (92%), attention-deficit/hyperactivity traits, and aggressive behaviors (63%). Six patients (43%) had seizures. Thirteen boys (93%) with *PLXNA3* variants showed novel or very low allele frequencies and probable damaging/disease-causing pathogenicity in one or more predictors. We found a genotype-phenotype correlation between *PLXNA3* cytoplasmic domain variants (exons 22 to 32) and more severe neurodevelopmental disorder phenotypes ( $P < 0.05$ ).

**Conclusions:** We report 14 boys with maternally inherited, hemizygous *PLXNA3* variants and a range of neurodevelopmental disorders suggesting a novel X-linked intellectual disability syndrome. Greater understanding of *PLXNA3* variant pathogenicity in humans will require additional clinical, computational, and experimental validation.

© 2021 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction

Neurodevelopmental disorders are complex and diverse disorders of the developing human brain. Clinical subclassification of neurodevelopmental disorders includes intellectual disabilities (ID) and autism spectrum disorders, which together (“autism/ID”) have a prevalence of approximately 3% to 5% of the population.<sup>1,2</sup> Primary (*genetically determined*) neurodevelopmental disorders lead to secondary (*functionally defined*) neurodevelopmental disabilities, which cause a range of neurological impairments as well as immeasurable humanistic and economic burden.<sup>3</sup>

A genetic etiology can be identified in over half of all neurodevelopmental disorders.<sup>4</sup> The integration of genomics into medical practice and the discovery of molecular diagnostic information has transformed the understanding of neurodevelopmental disorders. Over 2600 genes have been linked to autism/ID phenotypes according to multiple databases including Online Mendelian Inheritance in Man (OMIM), the Human Gene Mutation Database (HGMD), Human Phenotype Ontology (HPO), and the Simons Foundation Autism Research Initiative (SFARI).<sup>5–8</sup>

With the ongoing expansion and curation of human genetic variation databases, genetic testing of individuals with autism/ID phenotypes is providing more accurate diagnostic information for affected families and more research potential for the science community. However, genetic testing frequently identifies genetic variants of uncertain clinical significance. Such is currently the case for genetic variants within the family of nine plexin (*PLXN*) genes, whose protein products act as transmembrane receptors for semaphorin signaling proteins in the intracellular Ras GTPase activation in the developing nervous system.<sup>9–12</sup> Within the plexin family, *PLXNA3* (OMIM 300022; NCBI Reference Sequence: NM\_017514.5) is located on the X chromosome and encodes plexin-A3. Investigation of plexin-A3 knockout mice shows that plexin-A3 contributes to *Sema3F* and *Sema3A* signaling and regulates the development of hippocampal axonal projections *in vivo*.<sup>13</sup> This plexin-A3 protein is the most widely expressed in the fetal brain

and is also involved in cell motility, fasciculation, branching, and synapse formation.<sup>14,15</sup>

Currently, there is not enough open-access patient data to provide quantitative information about *PLXNA3*. We identified a *PLXNA3* variant in a teenage boy with unexplained severe ID and sought other boys with *PLXNA3*-related neurodevelopmental disorder phenotypes through two large clinical genetic variation databases (GeneDx and GeneMatcher).<sup>16</sup> The primary aim of this preliminary clinical study was to describe neurodevelopmental and neurocognitive phenotypes in boys with hemizygous *PLXNA3* variants. The secondary aim was to evaluate possible *PLXNA3* genotype-phenotype correlations.

## Methods

## Clinical data

We performed preliminary phenotyping on patients with rare hemizygous *PLXNA3* variants. Patients were identified through GeneDx and the global data exchange platform, GeneMatcher.<sup>16,17</sup> We included patients with rare *PLXNA3* variants reported as variants of uncertain significance in accordance with the 2015 American College of Medical Genetics and Genomics and the Association for Molecular Pathology standards and guidelines.<sup>18</sup>

## Case reports

We describe the proband in this study (Patient 1), who is a 17-year-old boy with longstanding severe autism/ID and a hemizygous *PLXNA3* variant identified on a trio GeneDx “Autism/ID Xpanded Panel,” which uses exome capture, next-generation sequencing, and targeted analysis of over 2000 genes associated with autism spectrum disorders and/or intellectual disability.<sup>19,20</sup> A formal case study was developed through family, caregiver, and teacher interviews; medical record reviews; and home and school observation sessions as a part of a medical school research project

(J.L.S.). We also describe a fetal subject that was excluded from the clinical outcome analysis.

### Case series

#### Data-sharing through GeneDx and GeneMatcher

All patients with *PLXNA3* variants in this study were either tested at GeneDx or identified through the global data exchange platform, GeneMatcher.<sup>16,17</sup> All GeneDx patients were identified following the “Autism/ID Xpanded” panel or exome sequencing performed by GeneDx (Gaithersburg, MD, USA) using the Clinical Research Exome kit (Agilent Technologies, Santa Clara, CA) or the IDT xGen Exome Research Panel v1.0 (Integrated DNA Technologies, Coralville, IA). All GeneDx-identified *PLXNA3* variants were reported as variants of uncertain significance in accordance with the 2015 American College of Medical Genetics and Genomics and the Association for Molecular Pathology standards and guidelines.<sup>18</sup>

#### Data collection

Participating physicians and genetic counselors of *PLXNA3* patients were contacted through GeneMatcher. Clinical data were obtained from the collaborating clinicians through the completion of a questionnaire, which allowed acquisition of clinical information including the reason for referral, relevant medical and neurodevelopmental histories, pertinent physical findings, clinical diagnoses, estimated level of cognitive functioning (i.e., mild, moderate, or severe intellectual disabilities), genetic test results, neuroimaging results, and any other pertinent laboratory findings. Informed consent for genetic testing was obtained from parents by their care team (Duo or Trio analysis) before testing. The research protocol (Exempt Research [no identifiers recorded during the creation of a de-identified data set] (45 CFR 164.502(d)(1))) was approved by two institutional review boards (IRBs) (University of Connecticut and Connecticut Children's).

#### Clinical outcome analysis: exclusion criteria

All boys in this study, except for the fetus in case report 2, had maternally inherited *PLXNA3* variants. For the clinical study analysis, we excluded the fetal subject with a *de novo* *PLXNA3* variant because of the absence of phenotype and neurodevelopmental outcome data.

#### Variant annotation, in silico, and gnomAD analysis

Variants were annotated based on *PLXNA3* transcript NM\_017514. *In silico* analyses for the missense variants were completed using Polyphen, Provean/Sift, Mutation Taster, and Combined Annotation-Dependent Depletion (CADD) to determine the likelihood of pathogenicity for each *PLXNA3* variant. The *in silico* analysis for the intronic insertion/splice variant was analyzed using Alamut. Predicted domain architecture information for the corresponding amino acids in the protein was retrieved from databases SMART, Prosite, InterPro, Pfam, and Regul@tionSpotter. The *PLXNA3* gene (search by genomic region: chrX:153,688,496-153,701,989 [GRCh37/hg19]) was analyzed from gnomAD (v2.1.1) database (<https://gnomad.broadinstitute.org/>), which contains genetic variants from 125,748 exome sequences and 15,708 genome sequences.<sup>21</sup> Annotation of variants was performed with the Ensembl Variant Effect Predictor for human genome assembly GRCh37.

#### Consent to participate

According to the stipulations of the IRBs at Connecticut Children's (IRB#19-075) and University of Connecticut (IRB#: 19X-193-

1), informed consent to participate in the study was obtained from the parent of the proband (Patient 1) and the parents of the fetus. No personal identifiable information was gathered from the other subjects, and the patients themselves were not in contact with the primary researcher.

#### Consent for publication

Consent for publication was obtained from the parent of the proband in accordance with the Connecticut Children's and University of Connecticut IRBs.

## Results

### Clinical manifestations

#### Proband description

The proband for this study (Patient 1) is a 17-year-old adolescent boy diagnosed with severe ID and an overlapping diagnosis of autism. He was born at term with macrosomia but without other prenatal or perinatal concerns. Cleft palate, torticollis, and low muscle tone were noted at birth. Attainment of developmental milestones lagged in all domains. Delayed gross motor development was remarkable for rolling at age six months, independent walking around three years, and running, jumping, and tricycle riding by grade school age. Maximally attained functional fine motor skills include self-feeding using weight-modified utensils, scribbling with palmar pencil grasp, and semi-independent teeth brushing, buttoning, and zipping. Limited communication skills in childhood were enhanced through picture exchange communication systems. Minimal sign language and spoken words emerged in later childhood with an estimated vocabulary of approximately 50 meaningful intelligible words at age 17 years. Estimated intelligence quotient is <30. He cannot count or read. Out-of-context short-phrase mimicry and repetitiveness (such as “I'm mad”) are common. Vision and hearing are normal. He has limited attention except for fixation on certain objects (such as balls). He responds to positive reinforcement behavioral modification and demonstrates empathy. Bouts of unprovoked screaming and aggressive, intimidating, and self-injurious behaviors during childhood necessitated a paraprofessional aide through state developmental disability services. By midadolescence, he has normal gross motor skills and is a proficient swimmer. He shows diminished pain responses and nonspecific sleep disturbances. Generalized seizures beginning in late infancy were well-controlled with valproic acid and lamotrigine, and his electroencephalography normalized. Risperidone was prescribed due to aggressive behavior. Genetic testing showed hemizygoty for a c.5023A>G (p.Thr1675Ala) *PLXNA3* variant—reported as a variant of uncertain significance. Variant segregation analysis showed heterozygoty for the c.5023A>G variant in the mother and an absence of this variant in the father and healthy brother (Tables 1–4).

#### Fetus description

This male fetus spontaneously aborted at 18 weeks' gestation secondary to hydrops fetalis with intrauterine fetal death. The mother was a 34-year-old G5P10SA4L1 woman of Polish/Italian descent, and the father was 39 years old and of Italian/Polish/Ukrainian descent. The otherwise healthy nonconsanguineous parents have normal karyotypes and no extended family history of multiple miscarriages, congenital abnormalities, or inherited conditions. The mother's maternal half-brother was diagnosed with ADHD, dyslexia, and learning disabilities. This fetus was the fourth male loss after the mother's fifth pregnancy; the parents have a healthy daughter. In the three previous male fetus losses, no

obvious cause for the recurrent losses could be identified. Chromosomal microarrays were normal for the third and fourth losses. The first male fetus loss was in the first trimester, and subsequent losses were in the second trimester. Pathology investigation of the second loss suggested ascending infection. This fetal autopsy showed extensive maceration, possible clinodactyly; fragments of kidney, adrenal, heart, liver, and lung with extensive autolysis; fragmented placenta, with a markedly hypercoiled umbilical cord (10 turns per 10 cm [normal, 1 to 3]); and features of intrauterine retention post-fetal death, including villous vascular stromal karyorrhexis. Exome sequencing showed hemizygoty for a *de novo* c.4970G>A (p.Arg1657Gln) *PLXNA3* variant.

**Data-sharing**

From April 2019 to June 2020, GeneMatcher identified 70 candidate patients with *PLXNA3* variants. After describing our proband (patient 1), we collaborated with genetic counselors and physicians caring for the 13 additional boys and single male fetus selected among the 70 identified patients with *PLXNA3* missense variants. Patients 1, 4, 5, 6, 8, 9, 10, 11, 12, and 13 and the fetus were tested at GeneDx, and Patients 2, 3, 7, and 14 were identified through GeneMatcher (tables). All GeneDx-identified variants were classified as variants of uncertain significance.

**Phenotype and clinical findings**

In this cohort of 14 boys with X-linked inherited *PLXNA3* variants, we found a range of neurodevelopmental disorders and other clinically defined diagnoses (Tables 1 and 2). All *PLXNA3* patients had a clinical diagnosis of autism or ID, or both, which was the original indication for performing a GeneDx autism/ID panel. Seven subjects (50%) had moderate-severe intellectual disabilities, and the other seven were described as having mild-moderate intellectual disabilities. All subjects except one (Patient 5) had an autism diagnosis. All subjects showed speech and language impairments. The most common additional clinical diagnoses were attention-deficit/hyperactivity disorder or other behavioral problems (10 of 14 [71%]) and fine motor impairments (13 of 14 [92%]) (Table 2). Six patients (43%) had a history of seizures. All head circumference measurements were in the normal range. Neuroimaging was performed in 11 patients, six of whom had no remarkable findings. In

the five boys with remarkable neuroimaging studies, no common pattern of abnormal neuroanatomic findings was apparent (Table 1 and Discussion).

**Molecular analysis**

All *PLXNA3* patients in this cohort were identified by autism/ID panel testing or exome sequencing (Table 3). We identified nine novel *PLXNA3* variants. A genotype-phenotype correlation could be suggested by the observation that all six *PLXNA3* patients with variants coding for amino acid changes in the Plexin A3 cytoplasmic domain (exons 22–32) showed severe neurodevelopmental disorder phenotypes (two-tailed Fisher’s exact test, *P* = 0.0097). None of the variants reported in this study were found in ClinVar (NM\_017514.5). Nine of the 14 variants from this study were not found in the gnomAD database. Four variants were present with an allele count of one and an allele frequency <1:100,000.

**In silico analysis**

Nine patients (64%) showed probably damaging/deleterious/disease-causing results in either all four *in silico* prediction models or the Alamut prediction model, and 13 subjects (93%) showed these results in at least one of the four *in silico* prediction models (Table 4). Of the nine patients with all four models or the Alamut model predicting pathogenicity, six had severe ID (67%). The single patient (patient 8) who had benign *in silico* prediction models also had a novel Plexin-A3 exon 13 extracellular domain variant (c.2494C>A/p.Gln832Lys) that correlated with a mild intellectual disability phenotype.

**Discussion**

Plexins are transmembrane receptors for semaphorin ligands that regulate multiple processes in the developing nervous system including cell migration and polarization, repulsive and attractive axonal guidance, laminar segregation, neuronal maturation, and apoptosis through intracellular Ras GTPase-activating protein (Ras-GAP) activation.<sup>9-12,15,22,23</sup> Over 30 semaphorins are categorized into eight classes, and the nine total plexins are grouped into four subfamilies (A to D; plexin-A1-A4, B1-B3, C,

**TABLE 1.** Clinical Findings in 14 Boys With Neurodevelopmental Disorders and *PLXNA3* Variants

Patient	Age (Years)	Seizures	Brain MRI	Family History
1 (Proband)	17	Yes	U	Healthy brother; <i>PLXNA3</i> negative
2	11	Yes	U	None
3	6	No	**	Healthy older sister and younger brother (not tested)
4	7	Yes	**	Sister with ID
5	3	No	U	Brother died as stillbirth; sister LD
6	8	No	U	Healthy brother (not <i>PLXNA3</i> tested); identity by descent
7	14	No	NA	Sister with autism
8	25	Yes	U	Brother with mild autism, <i>PLXNA3</i> negative
9	11	No	U	PKD, congenital deafness
10	2	No	**	None
11	16	Yes	**	Healthy brother; <i>PLXNA3</i> negative
12	18	Yes	**	None
13	13	No	NA	None
14	5	No	NA	Brother with speech delay; twin sisters died with pulmonary insufficiency of prematurity

Abbreviations:  
 ID = Intellectual disability  
 LD = Learning disability  
 MRI = Magnetic resonance imaging  
 NA = Not applicable  
 PKD = Polycystic kidney disease  
 U = Unremarkable/normal  
 \*\*: See Discussion for details.

**TABLE 2.**  
Developmental Findings in 14 Boys With Neurodevelopmental Disorders and *PLXNA3* Variants

Patient	Intellectual Disability Level	ASD or Other Behavioral Diagnoses	Motor Impairment (GM/FM)	Language Impairment	Prenatal/Perinatal Findings
1 (Proband)	Severe	ASD; ADHD, aggressive	-/+	Moderate-severe	LGA; cleft palate; torticollis
2	Moderate	ASD; ADHD, aggressive	+/+	Moderate-severe	Unknown
3	Mild-moderate	ASD; ADHD	+/+	Mild-moderate	Torticollis
4	Mild	ASD; ADHD, aggressive	-/+	Moderate-severe	Unknown
5	Mild-moderate	Cognitive rigidity	+/+	Moderate	Chylothorax
6	Severe	ASD; Aggression	-/+	Moderate-severe	Umbilical cord prolapse
7	Mild	ASD; OCD	-/-	Mild	IUGR
8	Mild	ASD; ADHD, anxiety	-/+	Moderate-severe	None
9	Mild-moderate	ASD; ADHD, anxiety, aggressive	+/+	Moderate-severe	None
10	Severe	ASD	+/+	Moderate-severe	IUGR
11	Severe	ASD; ADHD	+/+	Moderate-severe	None
12	Severe	ASD	+/+	Severe	None
13	Severe	ASD	+/+	Moderate-severe	None
14	Moderate-Severe	ASD	-/+	Severe	None

Abbreviations:

ADHD = Attention-deficit/hyperactivity disorder  
 ASD = Autism spectrum disorder  
 FM = Fine motor  
 GM = Gross motor  
 ID = Intellectual disabilities  
 IUGR = Intrauterine growth retardation  
 LGA = Large for gestational age  
 OCD = Obsessive-compulsive disorder

and D). *PLXNA3* is located on chromosome Xq28, and its major transcript consists of 33 exons (Fig 1). The encoded plexin-A3 protein is the most widely expressed plexin in sensory, sympathetic, and hippocampal neurons during early neurodevelopment when neurons are most responsive to semaphorins. Plexin-A3 is a specific receptor for the semaphorins SEMA3A and SEMA3F, which bind with the coreceptor neuropilin-1 to modulate its cytoplasmic domain for the activation of downstream intracellular signaling events (Fig 2).<sup>24</sup> Plexin-A3 knockout mice show

direct functional evidence for signaling roles such as guidance of sympathetic and hippocampal axons *in vivo*.<sup>13</sup> In zebrafish embryos, *Plxna3* mutations act as an essential component for *Sema3a1* signaling for fasciculation and target selection of the extending axons of motoneurons.<sup>25</sup> Although disruptions in axonal outgrowth and pathfinding are highly relevant to the broad autism/ID phenotype, the functional importance of *PLXNA3* missense variants and their clinical manifestations in human neurodevelopment are yet to be fully explained.

**TABLE 3.**  
Molecular Genetic Findings in 14 Boys With Neurodevelopmental Disorders and One Male Fetus With *PLXNA3* Variants (Reference Transcript NM\_017514)

Patient	Coding DNA Sequence Variant	Protein Sequence Variant	Splice Sites Abrogation	Exon: Chromosome Position	VEP Annotation	Other Genetic Findings
1 (Proband)	c.5023A>G	p.T1675A	No	30:153698821	Missense	2 small maternally inherited duplications, VUS
2	c.653T>C	p.L218S	No	3:153689497	Missense	-
3	c.1143G>C	p.Q381H	No	4:153690476	Missense	13q12.12 deletion, VUS
4	c.1400T>A	p.L467H	No	5:153691816	Missense	Maternally inherited, pathogenic GLMN variant (c.743dupT, p.Leu248Phefs*14)
5	c.2041G>A	p.E681K	Yes	10:153693209	Missense	Microarray: regions of homozygosity 251 Mb
6	c.2342C>G	p.A781G	Yes	13:153694000	Missense	-
7	c.2363C>T	p.A788V	No	13:153694021	Missense	-
8	c.2494C>A	p.Q832K	No	13:153694152	Missense	-
9	c.3407T>C	p.L1136P	No	19:153695780	Missense	76-kb duplication on chr 10q24.32
10	c.4250C>T	p.T1417I	No	24:153697035	Missense	Maternally inherited homoplasmic MT-TC variant m.5786dupT-
11	c.4601G>A	p.R1534H	Yes	27:153697728	Missense	520-kb gain-of-material VUS at 3p21.1 (includes <i>TKT</i> and exons 1-8 of <i>CACNA1D</i> )
12	c.4616C>G	p.T1539S	Yes	27:153697743	Missense	Heterozygous VUS in <i>CTNND2</i> (c.859C>T, p.P287S)
13	c.5041C>A	p.H1681N	No	30:153698839	Missense	48-kb VUS duplication on chr 7p14.1 with 12.13% regions of homozygosity
14 Fetus	c.5156+1G>T	-	Yes		Intron	Spontaneous miscarriage at 18 weeks' gestation, see text
	c.4970G>A	p.R1657Q	No		Missense	-

Abbreviations:

MT-TC = Mitochondrial  
 N = Normal/neutral  
 NMV = No matching variants  
 VEP = Variant Effect Predictor  
 VUS = Variant of uncertain significance

**TABLE 4.**  
In Silico and gnomAD Analysis in 14 Boys With Neurodevelopmental Disorders and One Male Fetus With PLXNA3 Variants

Patient	In Silico Analysis/Functional Effect Prediction				CADD Score (PHRED-like)	ClinVar NM_017514.5	Allele Frequency in gnomAD*† Hemizygotes
	PolyPhen-2 HumVar	Mutation Taster	Provean (Cutoff -2.5)	Sift (Cutoff 0.05)			
1 (Proband)	<b>0.969 PD</b>	<b>0.999 DC</b>	<b>-4.56 D</b>	<b>0.002 D</b>	25.3	NMV	5.49e-6/0
2	<b>0.627 PD</b>	<b>0.917 DC</b>	-0.75 N	0.32 T	22.8	NMV	NMV
3	<b>0.907 PD</b>	<b>0.999 DC</b>	<b>-3.28 D</b>	<b>0.022 D</b>	25.3	NMV	2.68e-5/1
4	0.125 B	<b>0.818 DC</b>	<b>-2.9 D</b>	0.25 T	21.7	NMV	NMV
5	<b>0.661 PD</b>	<b>0.999 DC</b>	<b>-2.69 D</b>	<b>0.041 D</b>	30	NMV	NMV
6	0.155 B	<b>0.999 DC</b>	<b>-3.11 D</b>	<b>0.001 D</b>	25	NMV	NMV
7	<b>0.833 PD</b>	<b>0.999 DC</b>	<b>-2.74 D</b>	0.263 T	24.3	NMV	5.54e-6/1
8	0.004 B	0.51 PP	-1.01 N	0.454 T	16.59	NMV	5.70e-6/0
9	<b>0.997 PD</b>	<b>0.999 DC</b>	<b>-5.0 D</b>	<b>0.003 D</b>	27.8	NMV	NMV
10	<b>0.959 PD</b>	<b>0.999 DC</b>	<b>-4.71 D</b>	<b>0.001 D</b>	27.2	NMV	NMV
11	<b>1.00 PD</b>	<b>0.999 DC</b>	<b>-4.29 D</b>	<b>0.001 D</b>	32	NMV	NMV
12	0.003 B	<b>0.935 DC</b>	0.32 N	<b>0.035 D</b>	22.4	NMV	5.49e-6/0
13	<b>0.969 PD</b>	<b>0.999 DC</b>	<b>-5.99 D</b>	<b>0.026 D</b>	24.8	NMV	NMV
14	<b>Alamut score -1†</b>	-	-	-	-	NMV	NMV
Fetus	<b>1.0 PD</b>	<b>0.999 DC</b>	<b>-3.57 D</b>	<b>0 D</b>	-	NMV	5.58e-6/0

Abbreviations:

B = Benign

CADD = Combined Annotation-Dependent Depletion

D = Deleterious/damaging

DC = Disease causing

N = Normal/neutral

NMV = No matching variants

PD = Probably damaging

PP = Prediction polymorphism; Slice sites, alteration within used splice site, likely to disturb normal splicing

T = Tolerated

\* Global allele frequency in gnomAD (v2.1.1), N = 141,456 exomes and genomes.


† Number.

‡ Predicted to cause abnormal gene splicing by destroying the canonical splice donor site in intron 30.


We describe 14 boys with maternally inherited *PLXNA3* variants and a range of neurodevelopmental disorder phenotypes, which suggests the possibility of variable expressivity in *PLXNA3* disorders. All subjects showed impairments in cognition and verbal communication with varying degrees of severity. The composite impression of the boys in this cohort did not suggest a physically recognizable phenotype, even if Patient 1 had a cleft palate, and in addition mild nonspecific facial features were described in four patients including hypotonic face with a bowed upper lip (Patient 2); synophrys, upturned ear lobules, and a prominent nasal bridge (Patient 6); a narrow face (Patient 8); and hooded eyelids with focal patchy hyperpigmentation (Patient 14).

Similarly, we did not observe a recurring neuroimaging prototype in this study. Of the 11 *PLXNA3* patients who had neuroimaging, six were reportedly unremarkable and five showed

anomalies including a thin corpus callosum with possible dysplastic splenium and posterior white matter (patient 3), periautrial white matter and centrum semiovale with white matter volume loss (Patient 4), large lateral ventricles and cerebrospinal fluid spaces (patient 10), dysmorphic medial temporal lobes and hippocampal architecture with adjacent subcortical white matter volume loss (patient 11), and low white matter volume (patient 12). In general, there is limited neuroimaging understanding of how such axonal guidance disorders in human case reports may result in normal or abnormal tissue morphology. In plexinA1-deficient (knockout) mice (similar to plexinA3, plexinD1, and L1CAM), immunohistochemistry in embryonic brains demonstrates the essential role of plexin-mediated cell adhesion of cingulate axons and the midline crossing of callosal axons during corpus callosum development.<sup>26</sup>



**FIGURE 1.** Representation of *PLXNA3* and its plexinA3 protein structure. The 33 exons of the *PLXNA3* gene are represented by boxes; introns are represented by a solid line. Distribution of novel *PLXNA3* variants and their exon distribution (arrows) corresponding to extracellular, transmembrane, and cytoplasmic plexinA3 domains. Patients with a *PLXNA3* variants and severe autism/intellectual disabilities phenotype are highlighted in bold followed by an asterisk (\*). Patients with mild-moderate autism/intellectual disabilities phenotype are not bolded and followed by a cross (†). The fetus with the c.4970G>A variant was excluded from analysis (#) (see text). IPT, immunoglobulin-like fold shared by plexins and transcription factors; PSI, Plexin, Semaphorin, and Integrin domains; T, transmembrane; H, helix coiled coil; TIG, Immunoglobulin (Ig) domain shared by Plexins and Transcription factors. The color version of this figure is available in the online edition.



**FIGURE 2.** Schematic representation of the extracellular, transmembrane, and cytoplasmic regions of the four PLXNA semaphorin receptor structures and their corresponding semaphorin subtypes. R-Ras, Ras-related protein; Rap-1, Ras-proximate-1. The color version of this figure is available in the online edition.

In this preliminary study, all 14 boys included for analysis had documented maternally inherited *PLXNA3* variants. The likely pathogenicity of *PLXNA3* is suggested by the absence of such variants in the unaffected, neurologically healthy brothers of Patients 1 and 11 in this study as well as the likely projected deleterious/damaging and disease-causing consequences by *in silico* predictors. The absence of clinical reports about these *PLXNA3* variants and the absence or rarity of these variants in the Genome Aggregation Database (gnomAD) further supports pathogenicity.

The male fetus described in this report had a *de novo* *PLXNA3* variant. Future studies should examine the significance of *de novo* *PLXNA3* variants and the role of germline mosaicism in plexin-related developmental disorders. No female subjects were reported in this cohort, but as genomic databases grow the possibility of finding girls with neurodevelopmental disorders and heterozygous *PLXNA3* variants with random X inactivation is likely.

An endocrinology study of patients with hypogonadotropic hypogonadism found loss-of-function variants in *SEMA3F* and *PLXNA3*, where six of the seven reported patients with *PLXNA3* variants had affected extracellular ligand and coreceptor interactions based on the structural model of the protein (i.e., three in the SEMA binding domain, two in the Plexin-Semaphorin-Integrin [PSI2] domain, and one in the Ig domain [IPT3 region])<sup>27</sup> (see protein domains illustrated in Fig 1). The sole hypogonadotropic hypogonadism subject who had a cytoplasmic *PLXNA3* variant was a female patient.<sup>27</sup> None of the boys in our study were diagnosed with hypogonadotropic hypogonadism.

In our cohort, the most severe neurodevelopmental disorder phenotypes were associated with *PLXNA3* cytoplasmic domain variants (exons 22 to 32 in Fig 1). Although the exact reason for this apparent genotype-phenotype correlation remains uncertain, plexins are known to have highly conserved cytoplasmic domains that contain GAP and GAP-like motifs for regulating molecules such as R-Ras, a RAS family member whose function includes regulation of integrin-dependent adhesion and other downstream intracellular processes<sup>28,29</sup> (Fig 2). In mouse embryos, deletion of the highly conserved plexin cytoplasmic domain creates a dominant-negative effect on their response to the repulsive Sema3A signal.<sup>30</sup> Such findings demonstrate the repulsive (or inhibitory) effects of Sema3A that are mediated by plexin/neuropilin

complexes and require the large and highly conserved cytoplasmic plexin domain to activate the downstream signal transduction machinery leading to the cell-type specific repulsive and attractive effects on axons.

Other transmembrane proteins can act as coreceptors or receptors for semaphorins and neuropilin/plexin receptor complexes, such as cell adhesion molecules, integrins, and proteoglycans such as heparan sulfate (perlecan), chondroitin sulfate, and keratan sulfate (lumican) proteoglycans<sup>12,31–33</sup> (Fig 2). The relationship between keratan sulfate proteoglycan, the most abundant glycosaminoglycan chain in the developing nervous system, and semaphorin-plexin signaling remains to be fully defined.<sup>34</sup> Keratan sulfate is an essential extracellular matrix fibrillogranular protein that guides axonal trajectory in the developing central nervous system by surrounding axonal fascicles to prevent axonal exit before they reach their programmed destination and by preserving the purity of axonal contents of white matter tracts.<sup>35</sup> Keratan sulfate ensheathment of axons within central tracts occurs several months before the initiation of myelination of those axons. An example is alobar/semilobar holoprosencephaly, where keratan sulfate ensheathes individual axons in the developing fetal brain, further isolating them and perhaps helping to explain why up to 40% of infants with holoprosencephaly do not have epilepsy despite the finding of severe dyslamination of their cerebral cortices.<sup>36</sup>

In addition to their essential roles in prenatal neurogenesis, semaphorin/plexin complexes have been implicated in various postnatal-onset disorders and diseases including gliogenesis, neurodegeneration, and malignancy.<sup>15,37</sup> *PLXNA4* variants have been linked to Alzheimer and Parkinson diseases.<sup>38,39</sup> The effects of plexin genes are demonstrated in the normal distribution of human intelligence ranging from presumed pathogenic variants in certain intellectual disabilities to enriched expression of plexin genes in extremely high intelligence.<sup>40</sup>

The limitations of this study include the challenges of any observational, cross-sectional, and retrospective study design. We acknowledge the challenge of finding a collective *PLXNA3* patient phenotype through the clinical descriptions by multiple clinicians with diverse training in genetics and pediatric neurology. Seven *PLXNA3* patients in this study had additional genetic or genomic variants. One patient (Patient 5) had a maternally inherited,



pathogenic *GLMN* variant, and six patients had genomic variants of uncertain significance including a small chromosome 13q12.12 deletion (Patient 4); a 76-kb duplication on chromosome 10q24.32 (Patient 10); a mitochondrial (MT-TC) variant (patient 11); a 520-kb duplication on chromosome 3p21.1 (Patient 12), which includes *TKT* and exons 1 to 8 of *CACNA1D*; a heterozygous *CTNND2* variant (patient 13); and a 48-kb chromosome 7p14.1 duplication (Patient 14) with 12% regions of homozygosity (suggesting consanguinity). The effect of these seven co-occurring variants on the range of intellectual disabilities and other features in this cohort is uncertain (Tables 1 and 2).

Although the proportion of X-linked genes involved in neurodevelopmental disorders is recognized to be higher than autosomal genes, less is known about the specific effects of many rare X-linked variants in complex traits such as cognition.<sup>41</sup> The *PLXNA3* predicted deleterious missense variants in our subjects are either novel or have a very low allele frequencies (less than 1/10,000), and thus the power of the loss-of-function observed/expected upper bound fraction metric (currently estimated as 0.384 for *PLXNA3*) is limited. However, the probability of loss-of-function intolerance ( $pLI \geq 0.9$ ) metric for *PLXNA3* predicts a high level of constraint.<sup>42</sup> In addition, it is not known whether pregnancies in asymptomatic women carrying pathogenic loss-of-function variants lead to natural selection with higher rates of fetal loss (suggested by case report 2 in this study) or the reduction of such *PLXNA3* variants in genetic studies of postnatally diagnosed neurodevelopmental disorders such as autism/ID.

Thus, it remains uncertain whether all of the maternally inherited hemizygous *PLXNA3* missense variants in our cohort are unambiguously benign or deleterious. One subject in this study (Patient 8) may have a likely benign *PLXNA3* variant. Similarly, our review of the *PLXNA3* literature and the very small number of previously reported patients with high-frequency *PLXNA3* missense variants suggests some may be likely benign.<sup>43</sup>

In summary, we describe a small cohort of boys with maternally inherited hemizygous *PLXNA3* variants and a range of neurodevelopmental disorders characterized by intellectual disabilities with codiagnosed autism, behavioral abnormalities, and epilepsy. These observations suggest a novel X-linked plexin intellectual disability syndrome. Additional clinical, computational, and neurobiological studies are needed to further elucidate *PLXNA3*-related developmental disorders especially in the setting of a familial X-linked inheritance pattern.

## Acknowledgments

The authors thank the parents who support children with neurodevelopmental disorders such as plexin-related neurogenetic disorders, and all molecular geneticists involved in the analysis and bioinformatic interpretation of genetic variants, including Dr. Boris Keren of Hôpital La Pitié Salpêtrière, Paris. We thank Carlos E. Prada, MD and Ronald R. Waclaw, PhD from Cincinnati Children's Hospital Medical Center for their support. For this study, Jacqueline L. Steel received a stipend from the University of Connecticut School of Medicine Summer Research Fellowship program.

## References

- Zablotsky B, Black LJ, Maenner MJ, et al. Prevalence and trends of developmental disabilities among children in the United States: 2009–2017. *Pediatrics*. 2019;144:e20190811.
- Wilfert AB, Sulovari A, Turner TN, Coe BP, Eichler EE. Recurrent de novo mutations in neurodevelopmental disorders: properties and clinical implications. *Genome Med*. 2017;9:101.
- Global Research on Developmental Disabilities. Developmental disabilities among children younger than 5 years in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Glob Health*. 2018;6:e1100–e1121.
- Hawrylycz MJ, Lein ES, Guillozet-Bongaarts AL, et al. An anatomically comprehensive atlas of the adult human brain transcriptome. *Nature*. 2012;489:391–399.
- McKusick VA. Online Mendelian inheritance in man, OMIM (TM). Available at: <http://www.ncbi.nlm.nih.gov/omim/>. Accessed October 6, 2021.
- Stenson PD, Mort M, Ball EV, Shaw K, Phillips A, Cooper DN. The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. *Hum Genet*. 2014;133:1–9.
- Kohler S, Gargano M, Matentzoglou N, et al. The human phenotype ontology in 2021. *Nucleic Acids Res*. 2021;49:D1207–D1217.
- Di Nanni N, Bersanelli M, Cupaioli FA, Milanese L, Mezzelani A, Mosca E. Network-based integrative analysis of genomics, epigenomics and transcriptomics in autism spectrum disorders. *Int J Mol Sci*. 2019;20:3363.
- Tamagnone L, Artigiani S, Chen H, et al. Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. *Cell*. 1999;99:71–80.
- Hota PK, Buck M. Plexin structures are coming: opportunities for multilevel investigations of semaphorin guidance receptors, their cell signaling mechanisms, and functions. *Cell Mol Life Sci*. 2012;69:3765–3805.
- Kruger RP, Abrandt J, Guan KL. Semaphorins command cells to move. *Nat Rev Mol Cell Biol*. 2005;6:789–800.
- Zhou Y, Gunput RA, Pasterkamp RJ. Semaphorin signaling: progress made and promises ahead. *Trends Biochem Sci*. 2008;33:161–170.
- Cheng HJ, Bagri A, Yaron A, Stein E, Pleasure SJ, Tessier-Lavigne M. Plexin-A3 mediates semaphorin signaling and regulates the development of hippocampal axonal projections. *Neuron*. 2001;32:249–263.
- Bagri A, Cheng HJ, Yaron A, Pleasure SJ, Tessier-Lavigne M. Stereotyped pruning of long hippocampal axon branches triggered by retraction inducers of the semaphorin family. *Cell*. 2003;113:285–299.
- Limoni G, Niquille M. Semaphorins and plexins in central nervous system patterning: the key to it all? *Curr Opin Neurobiol*. 2021;66:224–232.
- Bruel AL, Vitobello A, Mau-Them FT, et al. 2.5 years' experience of GeneMatcher data-sharing: a powerful tool for identifying new genes responsible for rare diseases. *Genet Med*. 2019;21:1657–1661.
- Sobreira N, Schiettecatte F, Valle D, Hamosh A. GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. *Hum Mutat*. 2015;36:928–930.
- Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*. 2015;17:405–424.
- Tweedie S, Braschi B, Gray K, et al. Genenames.org: the HGNC and VGNC resources in 2021. *Nucleic Acids Res*. 2021;49:D939–D946.
- Guillen Sacoto MJ, Tchasovnikarova IA, Torti E, et al. De novo variants in the ATPase module of *MORC2* cause a neurodevelopmental disorder with growth retardation and variable craniofacial dysmorphism. *Am J Hum Genet*. 2020;107:352–363.
- Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature*. 2020;581:434–443.
- Junqueira Alves C, Yotoko K, Zou H, Friedel RH. Origin and evolution of plexins, semaphorins, and met receptor tyrosine kinases. *Sci Rep*. 2019;9:1970.
- Giraudon P, Vincent P, Vuaillet C, et al. Semaphorin CD100 from activated T lymphocytes induces process extension collapse in oligodendrocytes and death of immature neural cells. *J Immunol*. 2004;172:1246–1255.
- Gil V, Del Rio JA. Functions of plexins/neuropilins and their ligands during hippocampal development and neurodegeneration. *Cells*. 2019;8:206.
- Tanaka H, Maeda R, Shoji W, et al. Novel mutations affecting axon guidance in zebrafish and a role for plexin signalling in the guidance of trigeminal and facial nerve axons. *Development*. 2007;134:3259–3269.
- Hossain MM, Tsuzuki T, Sakakibara K, et al. PlexinA1 is crucial for the midline crossing of callosal axons during corpus callosum development in BALB/cAJ mice. *PLoS One*. 2019;14:e0221440.
- Kotan LD, Ternier G, Cakir AD, et al. Loss-of-function variants in *SEMA3F* and *PLXNA3* encoding semaphorin-3F and its receptor plexin-A3 respectively cause idiopathic hypogonadotropic hypogonadism. *Genet Med*. 2021;23:1008–1016.
- Oinuma I, Ishikawa Y, Katoh H, Negishi M. The Semaphorin 4D receptor Plexin-B1 is a GTPase activating protein for R-Ras. *Science*. 2004;305:862–865.
- Kong Y, Janssen BJ, Malinauskas T, et al. Structural basis for plexin activation and regulation. *Neuron*. 2016;91:548–560.
- Rohm B, Ottemeyer A, Lohrum M, Puschel AW. Plexin/neuropilin complexes mediate repulsion by the axonal guidance signal semaphorin 3A. *Mech Dev*. 2000;93:95–104.
- De Wit J, De Winter F, Klooster J, Verhaagen J. Semaphorin 3A displays a punctate distribution on the surface of neuronal cells and interacts with proteoglycans in the extracellular matrix. *Mol Cell Neurosci*. 2005;29:40–55.
- Kantor DB, Chivatakarn O, Peer KL, et al. Semaphorin 5A is a bifunctional axon guidance cue regulated by heparan and chondroitin sulfate proteoglycans. *Neuron*. 2004;44:961–975.
- Cho JY, Chak K, Andreone BJ, Wooley JR, Kolodkin AL. The extracellular matrix proteoglycan perlecan facilitates transmembrane semaphorin-mediated repulsive guidance. *Genes Dev*. 2012;26:2222–2235.

34. Caterson B, Melrose J. Keratan sulfate, a complex glycosaminoglycan with unique functional capability. *Glycobiology*. 2018;28:182–206.
35. Sarnat HB. Proteoglycan (keratan sulfate) barrier in developing human forebrain isolates cortical epileptic networks from deep heterotopia, insulates axonal fascicles, and explains why axosomatic synapses are inhibitory. *J Neuropathol Exp Neurol*. 2019;78:1147–1159.
36. Sarnat HB, Yu W, Flores-Sarnat L. Keratan sulfate proteoglycan as an axonal insulating barrier in the forebrain of fetuses with alobar/semi-lobar holoprosencephaly. *Clin Neuropathol*. 2021;40:70–86.
37. Angelucci C, Lama G, Sica G. Multifaceted functional role of semaphorins in glioblastoma. *Int J Mol Sci*. 2019;20:2144.
38. Han Q, Sun YA, Zong Y, et al. Common variants in PLXNA4 and correlation to CSF-related phenotypes in Alzheimer's disease. *Front Neurosci*. 2018;12:946.
39. Schulte EC, Stahl I, Czamara D, et al. Rare variants in PLXNA4 and Parkinson's disease. *PLoS One*. 2013;8:e79145.
40. Zabaneh D, Krapohl E, Gaspar HA, et al. A genome-wide association study for extremely high intelligence. *Mol Psychiatry*. 2018;23:1226–1232.
41. Martin HC, Gardner EJ, Samocha KE, et al. The contribution of X-linked coding variation to severe developmental disorders. *Nat Commun*. 2021;12:627.
42. Wang T, Zhang Y, Liu L, et al. Targeted sequencing and integrative analysis of 3,195 Chinese patients with neurodevelopmental disorders prioritized 26 novel candidate genes. *J Genet Genomics*. 2021;48:312–323.
43. Athanasakis E, Licastro D, Faletra F, et al. Next generation sequencing in non-syndromic intellectual disability: from a negative molecular karyotype to a possible causative mutation detection. *Am J Med Genet A*. 2014;164A:170–176.